The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased federal oversight.
Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Investing.com -- Maze Therapeutics Inc (NASDAQ: MAZE ) received bullish coverage from multiple analysts, with Guggenheim, ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...
The partners will test Summit’s ivonescimab alongside Pfizer’s antibody-drug conjugates in hopes of finding “potentially ...
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...
A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...
Bluebird bio went public in 2013, raising approximately $116m through its IPO. The company has developed three US Food and Drug Administration (FDA)-approved gene therapy products, including Zynteglo ...